Fundraising FoxFormic Ventures — 2019 Investments
2 investments dated 2019 · listed companies and verified rows first · show all
Cyclarity Therapeutics develops engineered cyclodextrin drugs that target and remove toxic oxidized cholesterol (7-ketocholesterol) to treat atherosclerosis and other age-related diseases.
BiotechDeep TechHealthtechLongevityMedical DevicesNovato, US
Matthew O'Connor(Dr.)inAmelia Anderson(Co-Founder & Director of Scientific Computing / Computational Chemistry)inMike Kope(Co-CEO)Frank Schueler(Director)
Co-investorsSeed Healthcare
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Schrödinger
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.